Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 140
    Published on February 22, 2017


Drug To Treat Infection Behind Cardiovascular Disease

A Nutra-Pharmaceuticals class drug developed by UK based Lycotec Ltd for the treatment of a bacterial infection has filed a patent application. The new drug molecules are of food origin present in the Mediterranean diet and safe to consume. This is a first drug for the treatment of a bacterial infection that causes the development of cardiovascular disease (CVD) and atherosclerosis in an individual. In atherosclerotic plaques of people with cardiovascular disease (CVD), researchers identified a number of viruses and bacteria during the last three decades. Infections due to these bacteria and viruses are the reasons for the bad condition of atherosclerosis and CVD.



Lycotec drugs to treat bacterial infection causing cardiovascular disease CVD plaque atherosclerosis.

In multiple clinical studies, administration of this oral drug for 4 weeks duration has reduced anti-chlamydia antibodies and blood markers of oxidative-inflammatory damage in 85 percent of the patients with cardiovascular disease with double-blind and placebo-controlled individuals. The manufacturer is going to present the drug and clinical trial results at CBRS Conference in Charlotte, NC, in April 2017. Lycotec company is currently looking for a funding deal with other pharma company. One of the inventors of this drug is Dr. Ivan Petyaev, founder of Lycotec. Co-author of this invention is Prof Nailya Zigangirova.




Facebook     GooglePlus     Twitter
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Risks With Infections In Children
2. Risk With Depression To Cardiovascular Diseases
3. Cardiovascular Disease Survival Prediction
4. DPP-4 Inhibitor Linagliptin Tradjenta Prevents Cardiovascular Disease (CVD)
5. Dyslipidemia And Risks Of Cardiovascular Disease (CVD) And Ischemic Heart Disease (IHD)

 

 

About Qtern Combination Drug From AstraZeneca


DPP-4 Saxagliptin & SGLT2 Dapagliflozin Qtern drug to control (glycemic) blood sugar glucose levels.

Type ii diabetes (T2D) patients in the UK got a new treatment option to control their blood sugar levels with the availability of FDA approved qtern drug from AstraZeneca. It is a fixed combination drug of 5 mg DPP-4 inhibitor (saxagliptin) and 10 mg SGLT2 inhibitor (dapagliflozin), to be used once in a day. The drug was approved by the European Union during July 2016 intended to improve glycemic control in type 2 diabetes patients when


  • The patient is already under the treatment of free combination of saxagliptin and dapagliflozin
  • Glycemic control was not achieved with the components of qtern



Facebook     GooglePlus     Twitter
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. About Qtern Drug
2. Chronic Kidney Disease, Heart Disease & Diabetes Prevention Drugs From Forxiga Drug Maker AstraZeneca
3. Approval Of AstraZeneca's Diabetes Combination
4. Wearable Technology In Elder Care
5. About Meizus H1 Wearable Device

 

 

Medical Cost Savings With Triglyceride And Statin Reducing Treatments

The blood condition in an individual with high levels of triglycerides, fat phospholipids and LDL cholesterol is known as dyslipidemia. Dyslipidemia blood condition is associated with the huge costs (price) to manage complications due to type 2 diabetes (T2D) condition. On the average, an American individual is spending $13,700 to take care of diabetes condition, according to the ADA. Researchers from Kaiser Permanente, based in California, United States says medical costs can be reduced with triglyceride lowering therapy in type ii diabetes (T2D) patients. Researchers conducted observational studies among 184,000 type 2 diabetes patients. Researchers compared triglyceride levels and medical costs before and after treatment intended to lower cholesterol and triglyceride levels. Study results show


  • Diabetes patients can get economic benefits with all types of lipid-lowering treatments.
  • More than average savings in medical costs when patients receive both statin and triglyceride (TG) combination therapy when compared with a diabetic individual undergoing either triglyceride (TG) or statin therapy.
  • Medical cost savings are marginally more with triglyceride (TG) monotherapy compared with statin monotherapy.
  • A statin and triglyceride (TG) combination therapy intended to reduce triglycerides by more than 30 percent got the maximum economic benefit.
  • A diabetes individual can save maximum economic benefit with a statin monotherapy with the reduction of triglycerides by more than 30 percent but to lesser amount compared with combination therapy.

Triglyceride fat lipid LDL reducing statin treatment in dyslipidemia diabetes patients to save cost.

But researchers unable to say the economic saving is due to the treatments or due to a reduction in triglyceride levels. The study findings were published in the American Journal of Cardiology.




Facebook     GooglePlus     Twitter
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. About Afrezza Cost Effective Insulin Drug
2. Insulin Related Cancer Risk Offset Benefits With Statins Usage
3. Benefits With Statins Usage
4. Wearable Devices Market
5. Wearable Device To Alleviate Stress and Anxiety

 

 

 

Site maps

Site map 1   Site map 2   Site map 3   Site map 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.